Published in Am J Cardiol on April 15, 1995
Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed (2007) 1.73
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice. J Gen Intern Med (1997) 1.36
Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich) (2010) 0.93
Losartan/Hydrochlorothiazide fixed combination versus amlodipine monotherapy in korean patients with mild to moderate hypertension. Korean Circ J (2009) 0.82
A pharmacovigilance study of antihypertensive medicines at a South delhi hospital. Indian J Pharm Sci (2009) 0.80
A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk. PLoS One (2015) 0.76
BMP signaling modulation attenuates cerebral arteriovenous malformation formation in a vertebrate model. J Cereb Blood Flow Metab (2014) 0.76
Efficacy and Tolerability of Nilvadipine in Combination with an Angiotensin II Receptor Antagonist in Patients with Essential Hypertension: A Multicenter, Open-Label, Uncontrolled Study. Curr Ther Res Clin Exp (2003) 0.75
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan. Vasc Health Risk Manag (2013) 0.75
A new class of angiotensin-converting enzyme inhibitors. Nature (1980) 3.03
Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther (1981) 1.44
Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens (1995) 1.40
Potentiation of adrenergic venomotor responses by angiotensin, prostaglandin F 2 and cocaine. J Pharmacol Exp Ther (1971) 1.26
Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther (1981) 1.22
Attenuation of hydrochlorothiazide-induced hypokalemia in dogs by a beta-adrenergic blocking drug, timolol. Eur J Pharmacol (1975) 1.20
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution. J Med Chem (1980) 0.97
Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 0.95
Differential effects of prostaglandins E 1 , E 2 , F 1 and F 2 on adrenergic vasoconstriction in the dog hindpaw. J Pharmacol Exp Ther (1971) 0.95
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med (1996) 0.94
In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther (1992) 0.92
Initial evaluation of transdermal timolol: serum concentrations and beta-blockade. J Cardiovasc Pharmacol (1985) 0.88
Enhancement of the antihypertensive effect of hydrochlorothiazide in dogs after suppression of renin release by beta-adrenergic blockade. Clin Sci Mol Med (1975) 0.87
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension (1995) 0.86
Central inhibition of reflex vasodilatation by angiotensin and reduced renal pressure. Am J Physiol (1970) 0.86
Influence of angiotensin I, angiontensin II and cocaine on adrenergic vasoconstrictor responses in the dog hindpaw. J Pharmacol Exp Ther (1972) 0.86
Enhancement of sympathetic neurotransmission by prostaglandin F 2 in the cutaneous vascular bed of the dog. Eur J Pharmacol (1972) 0.86
Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press (1996) 0.86
Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens (1995) 0.84
Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421). Fed Proc (1983) 0.83
Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens Suppl (1995) 0.83
Cardiac and hemodynamic responses to synthetic atrial natriuretic factor in rats. Life Sci (1987) 0.83
Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension (1998) 0.82
Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press (1997) 0.81
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists. J Med Chem (1991) 0.81
A new, long-lasting competitive inhibitor of angiotensin. Science (1972) 0.81
Another humoral substance that enhances adrenergic responsiveness during acute renal ischaemia. Nature (1971) 0.81
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens (1995) 0.80
3-Hydroxy-alpha-methyltyrosine progenitors: synthesis and evaluation of some (2-oxo-1,3-dioxol-4-yl)methyl esters. J Med Chem (1984) 0.80
Blockade of adrenergic vasoconstrictor responses in the dog by prostaglandins E 1 and A 1 . J Pharmacol Exp Ther (1971) 0.80
Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure. J Hypertens Suppl (1983) 0.79
Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol (1993) 0.79
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2. J Med Chem (1986) 0.79
Responses to amrinone in isolated cardiac muscles from cat, rabbit, and guinea pig. J Cardiovasc Pharmacol (1984) 0.79
Etiologic factors of recurrent abortion and subsequent reproductive performance of couples: have we made any progress in the past 10 years? Am J Obstet Gynecol (1992) 0.78
Hemodynamic effects of angiotensin and renin inhibition in dogs with acute left ventricular failure. Am J Med (1984) 0.78
Antihypertensive beta-adrenergic blocking agents: N-aralkyl analogues of 2-[3-(tert-butylamino)-2-hydroxypropoxy]-3-cyanopyridine. J Med Chem (1983) 0.78
Central antihypertensive properties of muscimol and related gamma-aminobutyric acid agonists and the interaction of muscimol with baroreceptor reflexes. Can J Physiol Pharmacol (1979) 0.78
Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clin Ther (1999) 0.78
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents. J Med Chem (1979) 0.78
beta-Adrenergic blocking agents with acute antihypertensive activity. J Med Chem (1979) 0.77
Measurement of cardiac output in anesthetized rats by dye dilution using a fiberoptic catheter. J Pharmacol Methods (1987) 0.77
MRI demonstration of ureteral jet effect in a patient with a spinal ganglioneuroma. Pediatr Radiol (1995) 0.77
Antagonism of peripheral and central effects of angiotensin II by (1-sarcosine, 8-isoleucine)angiotensin II. J Pharmacol Exp Ther (1973) 0.77
Central antihypertensive effects of inhibitors of the renin-angiotensin system in rats. Am J Physiol (1976) 0.77
Cardiac and noncardiac atrial natriuretic factor (ANF) biosynthesis and storage and plasma ANF in the rat model of chronic ventricular dysfunction. Endocrinology (1989) 0.77
Influence of prostaglandins on adrenergic transmission to vascular smooth muscle. Circ Res (1972) 0.77
New centrally acting antihypertensive drugs related to methyldopa and clonidine. Hypertension (1984) 0.77
Some cardiovascular effects of ST-91 and clonidine. Eur J Pharmacol (1977) 0.76
Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. Eur J Pharmacol (1981) 0.76
Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens (1996) 0.76
Approaches to vasodilating/beta-adrenergic blocking agents: examples of the dihydrolutidine type. J Med Chem (1981) 0.76
Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers. J Cardiovasc Pharmacol (1986) 0.76
Antihypertensive activity of metyrosine in spontaneously hypertensive rats and its enhancement by carbidopa. Clin Sci Mol Med Suppl (1978) 0.75
Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure. J Cardiovasc Pharmacol (1985) 0.75
Hemodynamic effects of synthetic atrial natriuretic factor (ANF) in dogs with acute left ventricular failure. Eur J Pharmacol (1985) 0.75
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine. J Med Chem (1980) 0.75
Comparative effects of enalapril, enalaprilic acid and captopril in blocking angiotensin I-induced pressor and dipsogenic responses in spontaneously hypertensive rats. Clin Exp Hypertens A (1984) 0.75
Central antihypertensive effects of propranolol in the spontaneously hypertensive rat. Neuropharmacology (1976) 0.75
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class. J Med Chem (1983) 0.75
Antihypertensive and hemodynamic properties of 2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine HCl (MK-761). J Pharmacol Exp Ther (1979) 0.75
Comparison of renin and converting enzyme inhibition in sodium-deficient dogs. Hypertension (1985) 0.75
Comparison of cardiovascular responses to the bradycardic drugs, alinidine, AQ-A 39, and mixidine, in the anesthetized dog. J Cardiovasc Pharmacol (1984) 0.75
11,12-secoprostaglandins. 6. Interphenylene analogues of acylhydroxyalkanoic acids and related compounds as renal vasodilators. J Med Chem (1983) 0.75
2-(Aminomethyl)phenols, a new class of saluretic agents. 6. Effects of N,O-spiroannulation and subsequent quaternization. J Med Chem (1983) 0.75
Renal function during consciousness and anesthesia in sheep: effects of renal vasodilation by papaverine and acetylcholine. J Pharmacol Exp Ther (1981) 0.75
Design and discovery in the development of long-acting renin inhibitors. Biochem Soc Trans (1990) 0.75
Antagonism of hydrochlorothiazide-induced elevations in plasma-renin activity by methyldopa in conscious renal-hypertensive dogs. Can J Physiol Pharmacol (1974) 0.75
Acute and subacute hemodynamic effects of enalaprilat, milrinone and combination therapy in rats with chronic left ventricular dysfunction. Clin Exp Hypertens A (1987) 0.75
A structurally novel stimulator of guanylate cyclase with long-lasting hypotensive activity in the dog. Eur J Pharmacol (1985) 0.75
Central noradrenergic control of blood pressure. Annu Rev Pharmacol Toxicol (1976) 0.75
Arterial hypertension elicited by prolonged intra-vertebral infusion of angiotensin II in conscious dog. Am J Physiol (1971) 0.75
2-(Aminomethyl)phenols, a new class of saluretic agents. 2. Synthesis and pharmacological properties of the 5-aza isostere of 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenol. J Med Chem (1981) 0.75
Depression of adrenergic transmission by a factor in renal venous blood: new evidence for an antihypertensive function of the kidney. Arch Int Pharmacodyn Ther (1972) 0.75
Changes in vascular reactivity and renal hemodynamics induced by benzyltrimethylammonium bromide (BTM). J Pharmacol Exp Ther (1972) 0.75
Antagonism of conditioned salivation in conscious dogs by antihypertensive drugs. Can J Physiol Pharmacol (1977) 0.75
Beta adrenoceptor blocking properties of MK-761. J Pharmacol Exp Ther (1979) 0.75
An approach to peripheral vasodilator-beta-adrenergic blocking agents. J Med Chem (1977) 0.75
An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Cardiovasc Drugs Ther (1996) 0.75
Diuretic and antihypertensive effects of 2-aminoethyl-4-(1,1-dimethylethyl)-6-iodophenol hydrochloride (MK-447). J Pharmacol Exp Ther (1979) 0.75
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. J Hypertens Suppl (1995) 0.75
Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol (1995) 0.75